Safety and cost savings of omitting cardiac surveillance during treatment with pegylated liposomal doxorubicin in gynecologic oncology survivors

Kushnir, Christina

351 - Poster Session B
Safety and cost savings of omitting cardiac surveillance during treatment with pegylated liposomal doxorubicin in gynecologic oncology survivors

Sunday, March 23, 2014: 10:00 AM

West Exhibit Hall (Tampa Convention Center)

C. L. Kushnir¹, A. Angarita¹, A. K. Sinno¹, S. D. Thompson¹, E. J. Tanner III¹, R. L. Giuntoli II¹, K. C. Long², A. A. Secord³ and A. Nickles Fader¹
¹Johns Hopkins Medical Institutions, Baltimore, MD, ²Memorial Sloan-Kettering Cancer Center, Brooklyn, NY, ³Duke University Medical Center, Durham, NC

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

351 - Poster Session B
Safety and cost savings of omitting cardiac surveillance during treatment with pegylated liposomal doxorubicin in gynecologic oncology survivors

351 - Poster Session B Safety and cost savings of omitting cardiac surveillance during treatment with pegylated liposomal doxorubicin in gynecologic oncology survivors

351 - Poster Session B
Safety and cost savings of omitting cardiac surveillance during treatment with pegylated liposomal doxorubicin in gynecologic oncology survivors